High-Dose Azithromycin versus High-Dose Amoxicillin-Clavulanate for Treatment of Children with Recurrent or Persistent Acute Otitis Media
Open Access
- 1 October 2003
- journal article
- clinical trial
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (10), 3179-3186
- https://doi.org/10.1128/aac.47.10.3179-3186.2003
Abstract
Infants and young children, especially those in day care, are at risk for recurrent or persistent acute otitis media (AOM). There are no data on oral alternatives to high-dose amoxicillin-clavulanate for treating AOM in these high-risk patients. In this double-blind, double-dummy multicenter clinical trial, we compared a novel, high-dose azithromycin regimen with high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent AOM. Three hundred four children were randomized; 300 received either high-dose azithromycin (20 mg/kg of body weight once a day for 3 days) or high-dose amoxicillin-clavulanate (90 mg/kg divided twice a day for 10 days). Tympanocentesis was performed at baseline; clinical response was assessed at day 12 to 16 and day 28 to 32. Two-thirds of patients were aged ≤2 years. A history of recurrent, persistent, or recurrent plus persistent AOM was noted in 67, 18, and 14% of patients, respectively. Pathogens were isolated from 163 of 296 intent-to-treat patients (55%). At day 12 to 16, clinical success rates for azithromycin and amoxicillin-clavulanate were comparable for all patients (86 versus 84%, respectively) and for children aged ≤2 years (85 versus 79%, respectively). At day 28 to 32, clinical success rates for azithromycin were superior to those for amoxicillin-clavulanate for all patients (72 versus 61%, respectively; P = 0.047) and for those aged ≤2 years (68 versus 51%, respectively; P = 0.017). Per-pathogen clinical efficacy against Streptococcus pneumoniae and Haemophilus influenzae was comparable between the two regimens. The rates of treatment-related adverse events for azithromycin and amoxicillin-clavulanate were 32 and 42%, respectively ( P = 0.095). Corresponding compliance rates were 99 and 93%, respectively ( P = 0.018). These data demonstrate the efficacy and safety of high-dose azithromycin for treating recurrent or persistent AOM.Keywords
This publication has 33 references indexed in Scilit:
- Efficacy of Single-Dose Azithromycin in Treatment of Acute Otitis Media in Children after a Baseline TympanocentesisAntimicrobial Agents and Chemotherapy, 2003
- Flaws in design and conduct of clinical trials in acute otitis mediaThe Pediatric Infectious Disease Journal, 2002
- Experimental Acute Otitis Media Due to NontypeableHaemophilus influenzae: Comparison of High and Low Azithromycin Doses with PlaceboAntimicrobial Agents and Chemotherapy, 2002
- Treatment of Acute Otitis Media Consensus RecommendationsClinical Pediatrics, 2002
- Mutations in 23S rRNA and Ribosomal Protein L4 Account for Resistance in Pneumococcal Strains Selected In Vitro by Macrolide PassageAntimicrobial Agents and Chemotherapy, 2000
- A multicenter, randomized, open label comparison of azithromycin and amoxicillin/clavulanate in acute otitis media among children attending day care or schoolThe Pediatric Infectious Disease Journal, 1996
- A multicenter, double blind comparison of azithromycin and amoxicillin/clavulanate for the treatment of acute otitis media in childrenThe Pediatric Infectious Disease Journal, 1996
- A multicenter, open label trial of azithromycin vs. amoxicillin/clavulanate for the management of acute otitis media in childrenThe Pediatric Infectious Disease Journal, 1996
- Management of pediatric patients with group A beta-hemolytic Streptococcus pharyngitisThe Pediatric Infectious Disease Journal, 1995
- Otitis MediaClinical Infectious Diseases, 1994